Overview

We were formed in 2014 by neuroscience researchers at the Swiss Federal Institute of Technology (EPFL). We are now headquartered at the High Tech Campus in Eindhoven, the Netherlands, with an office in Lausanne, Switzerland and a growing US team based in Boston, Massachusetts.

Meet the team

  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • John Murphy, PhD, CTO

    John Murphy, PhD

    Chief Technology Officer

    John Murphy has over 25 years of experience driving the development of medical implants and neurostimulation devices at LivaNova, Abbott, and Medtronic. His leadership expertise spans the continuum of R&D, with a focus on consumer-centric design, IP generation, and agile processes. Prior to joining ONWARD in 2020, John was the Chief Technology Officer of LivaNova Neuromodulation. He holds a BS in Electrical Engineering from the University of North Carolina at Charlotte and a PhD in Production Systems and Robotics from the Swiss Federal Institute of Technology (EPFL).
  • Grégoire Courtine, PhD, CSO

    Grégoire Courtine, PhD

    Chief Scientific Officer

    Prof. Grégoire Courtine is the co-founder of ONWARD and its Chief Scientific Officer as well as a Non-Executive Director. His ground-breaking research in neuroscience has been recognized by several prestigious prizes, including the Rolex Award, the Schellenberg Research Prize and the Chancellor’s Award of the University of California. Grégoire is a full professor of neuroscience and neurotechnology at the Swiss Federal Institute of Technology (EPFL) and Director of NeuroRestore, a research center at EPFL and the University Hospital of Lausanne that develops innovative therapies using neurostimulation and other approaches. He holds a PhD in Neurosciences from INSERM, Paris, and a PhD in Medicine from the University of Pavia, Italy.
  • Lara Smith Weber, CFO

    Lara Smith Weber

    Chief Financial Officer

    Lara Smith Weber brings over 25 years of finance, accounting, and strategy experience with life science companies in the United States and Europe. She most recently served as CFO and Head of Commercial Financial Planning and Analysis for MorphoSys, Inc., based in Boston, USA. Prior to that, Lara held various finance leadership roles at MorphoSys AG, based in Munich, Germany. Her roles included Senior VP, Head of Controlling and Corporate Finance, where she led a US$239M NASDAQ IPO in 2018. Previously, Lara spent 7 years at Telefonica Germany in a variety of finance leadership positions and worked for consulting firm, Booz Allen Hamilton, in Zurich, Switzerland. Lara earned a BA in German Studies and both a BS and M.Sc. in Electrical Engineering from Stanford University in Palo Alto, USA. She also earned an MBA from IMD in Lausanne, Switzerland.

Recent News

08 Dec 22
ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury
Low blood pressure is a major issue for people with spinal cord injury that impacts cardiovascular health and quality of life ARC Therapy resulted in immediate improvement in blood pressure regulation in all study participants
21 Nov 22
ONWARD Awarded European Innovation Council Grant to Further Develop Brain-Computer Interface Technology; Company also Wins First Place in 2022 Brain-Computer Interface Awards
EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA—November 21, 2022--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence
10 Nov 22
ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis
Data from all nine participants in STIMO trial published in Nature Researchers identify specific neurons activated and remodeled by spinal cord stimulation that enable patients to walk
08 Nov 22
ONWARD Reports Third Quarter 2022 Highlights and Provides Business Update
Two additional Breakthrough Device Designations granted by U.S. FDA for ARC Therapy Strong financial position with €70 million in cash and cash equivalents as of September 30, 2022, expected to fund operations through year-end 2024

Financial Calendar

More events are coming soon.

Recent Filings